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Abstract 
Proteomics, the large‑scale study of the structure and function of proteins of a cell or organism, is a rapidly developing 
area of biomedical research which is perfectly suited to the study of pediatric lung injury, where a variety of samples 
are easily, and repeatedly, accessible including plasma (reflecting a whole body response) and broncheoalveolar lung 
fluid (reflecting the lungs response). When applied to pediatric lung injury, proteomics could be used to develop 
much needed early biomarkers of lung injury, elucidate pathological pathways and determine protein alterations 
associated with specific disease processes. However despite the obvious benefits and need, proteomics is rarely uti‑
lized in studies of pediatric injury. This review primarily reports on the last decade of pediatric research into proteomes 
associated with specific respiratory diseases including bronchopulmonary dysplasia, respiratory infection, cystic 
fibrosis and asthma whilst also reflecting on the challenges unique to proteomic studies of the pediatric respiratory 
disease population. We conclude that the number of key pathological differences between the pediatric and adult 
study populations inhibit inference of results from adult studies onto a pediatric population and necessitate studies of 
the pediatric proteome. Furthermore the disparity amongst pediatric lung disease in terms of age at onset and under‑
lying pathological mechanism (genetic, immunological, intervention‑based, developmental arrest, inhaled toxin) will 
require proteomic studies which are well designed, with large disease specific patient sets to ensure adequate power 
as well as matched controls. Regardless of causative agent, pulmonary biomarkers are needed to predict the clinical 
course of pediatric lung disease, status, progression and response to treatment. Identification of early biomarkers is 
particularly pertinent in order to understand the natural history of disease and monitor progression so prevention of 
ongoing lung injury and impact on childhood can targeted.
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Adult lung disease from fetal origins: the long‑term 
impact of pediatric lung injury
Lung development can be divided into several distinct 
phases, starting with the embryonic phase followed by 
the pseudoglandular, canalicular, saccular, and alveolar 
phases; finally there is a prolonged phase of lung growth 
and maturity that is completed when the body growth 
stops [1]. Each of these distinct developmental phases 
is highly susceptible to influence by environmental 
stresses which may include reduced nutrient and oxygen 
availability, mechanical ventilator support, infection or 
inflammation and exposure to toxins such as tobacco 
smoke. By affecting lung development, early exposure to 
damaging environmental factors can lead to persistent 
alterations in lung structure and function which continue 
to adversely influence respiratory health throughout 
life. This is particularly pertinent in pediatrics, in which, 
unlike the adult population, respiratory illness remains 
the most common cause of illness in childhood. Further-
more, many serious pediatric respiratory illnesses are 
now not fatal in childhood and can now be considered 
chronic illnesses of which little is known about adult out-
comes. The potential for significant impact of early lung 
injury on outcome in adulthood, necessitates a need for 
studies of pediatric lung injury mechanisms.
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Proteomics is an underutilized resource in the 
study of pediatric lung injury
Proteomics, the large-scale study of the structure and 
function of proteins of a cell or organism, is a rapidly 
developing area of biomedical research which is perfectly 
suited to the study of pediatric lung injury, where a vari-
ety of samples are available for study including tissue, 
broncheoalveolar lung (BAL) fluid and serum. The goal 
of proteomics is to provide a snapshot of all proteins in 
a fluid, tissue or organism [2] with proteomic techniques 
commonly applied to identify disease specific proteins 
and protein patterns in biological samples [3]. Proteomic 
analysis has the advantage of studying: (1) networks of 
proteins that provide “real-time” status of disease state, 
(2) modulation of protein function by diseases and drugs, 
(3) gene activity, (4) pathogenesis of disease and (5) the 
prediction of new therapies [4]. When applied to pedi-
atric lung injury, these protein patterns could be used to 
develop much needed early biomarkers of lung injury, 
elucidate pathological pathways and determine protein 
alterations associated with specific disease processes. In 
particular, given the often rapid progression of disease in 
the very young, identification of early markers of disease 
progression, when the natural history of the disease can 
be altered, is essential.
Amongst the sample types available for the proteomic 
study of pediatric lung injury unique challenges and 
opportunities arise. Proteomic analysis of lung tissue 
provides an opportunity to directly study the proteome 
associated with lung injury and repair, however obtaining 
lung tissue in children and infants is rarely undertaken 
in clinical practice, technically challenging to do so as 
the disease site is often distal and sampling is associated 
with a higher risk of adverse outcomes than in adults. 
An alternative to tissue procurement is the study of BAL 
fluid, which specifically reflects the lung response. BAL 
is a complex mixture of soluble components such as 
phospholipids, neutral lipids, nucleic acids, peptides, and 
proteins derived from resident cells, or diffusion through 
the alveolar-capillary barrier [5]. The proteomic analy-
sis of BAL samples is potentially a powerful tool for the 
identification of proteomes linked to specific respiratory 
disease states, allowing us to further our understand-
ing of injury and repair processes within the immaturely 
developed lung. However, the study of BAL is not with-
out its own challenges; obtainment of BAL whilst gener-
ally considered safe and well tolerated is technically an 
invasive procedure with an associated risk of bleeding, 
barotrauma, need for intubation and sedation, severe 
hypoxia, and/or bronchospasm [6, 7]. Consequently, BAL 
sampling is usually only feasible in children and infants 
receiving critical care support, limiting utility to track 
chronic diseases. Furthermore, many factors can affect 
the composition of BAL fluid and therefore may impact 
on the reproducibility of study results, including place-
ment of the bronchoscope, total volume of saline instilled 
and risk of contamination with epithelial lining fluid [6]. 
These clinical and sampling concerns are circumnavi-
gated when plasma is employed in proteomic studies. 
Obtainment of serum samples is considered minimally 
invasive and low risk making it ideal for biomarker dis-
covery studies whilst the ability to perform repeated 
measurements facilitates the assessment of temporal pro-
teome changes. However changes within serum are often 
very small and reflect a wide range of both peripheral and 
central processes and therefore pinpointing changes spe-
cific to the respiratory disease being studied can be dif-
ficult. Furthermore the complexity of serum, in which 
there is a huge abundance of select proteins (albumin and 
immunoglobulins represent 75 % of the total weight [8]) 
may limit the detection of lower molecular weight pro-
teins by certain techniques such as mass spectrometry. 
This limitation can be partially overcome by perform-
ing fractionation prior to analysis to reduce complexity 
or by employing alternative discovery methods such as 
aptamer-based assays or SWATH-MS.
Despite the obvious benefits and need, whilst targeted 
ELISA-based approaches have been applied to the study 
of pediatric respiratory disease [9, 10], the non-targeted 
proteomics approach is rarely utilized in studies of pedi-
atric lung injury. This is clearly demonstrated when 
reviewing the last decade of proteomic research into lung 
disease during which only 4 % of studies have examined 
childhood respiratory disorders, compared with 61 % of 
proteomics studies which focused on adult lung cancer 
(Fig.  1). The low numbers of proteomic studies focused 
on lung injury in childhood may reflect the unique chal-
lenges faced by researchers when studying a pediatric 
population. The primary of which are the complications 
presented when studying a maturing organ system which 
is undergoing profound developmental changes from 
pre-birth through to birth and onto adolescence (Fig. 2). 
Further hindering pediatric studies of lung injury is the 
difficulty of obtaining pediatric subjects for research, 
paucity of tissue samples, and the difficulty of obtaining 
control samples from healthy children [11, 12]. A final 
contributory factor may be the heterogeneity of the pedi-
atric lung disease population which includes a variety 
of underlying pathologies including genetic alterations 
(cystic fibrosis), respiratory infection (bacterial and viral), 
allergy (wheeze, asthma) and intervention-induced or 
developmental arrest injury (bronchopulmonary dyspla-
sia) all of which are likely to produce differing proteome 
profiles.
Page 3 of 8Pereira‑Fantini and Tingay  Clin Proteom  (2016) 13:5 
Application of proteomic technology to the study 
of childhood lung disease
In a small number of studies proteomic techniques have 
been applied to the study of bronchopulmonary dysplasia 
(BPD), respiratory infection, cystic fibrosis and asthma. 
Details of these studies are summarized in Table  1 and 
included below.
Bronchopulmonary dysplasia (BPD)
Preterm birth is an increasing public health problem, 
with 15 million preterm infants born per year, of which 
1 million will die [13]. Respiratory failure remains the 
hallmark disease of prematurity, as the predominantly 
canalicular or saccular, and surfactant deficient, lung 
is required to commence gas exchange whilst at high 
risk of mechanical and inflammatory injury. BPD is the 
chronic manifestation of lung injury in the preterm lung, 
and the most common form of newborn lung disease 
[14]. BPD is a multi-factorial disease, with pathogenesis 
linked to immature lung tissue, atelectasis, volutrauma 
and mechanical shear force injury caused by mechani-
cal ventilation of the canalicular or saccular lung, oxidant 
injury, and pro-inflammatory mediators [15]. Despite 
improvements in neonatal care, BPD continues to occur 
in approximately one-third of newborns who have birth 
weights <1000  g and contributes to high mortality and 
long-term morbidity in this population [16]. Further-
more, BPD interrupts the usual alveolar developmental 
process well into childhood. Despite the high mortal-
ity within this population group, and a propensity for 
ongoing damage in survivors due to interrupted lung 
development [17], only a single study has examined the 
proteome of broncheoalveolar fluid (BAL) obtained from 
BPD and control infants [15]. Whilst the study numbers 
Fig. 1 Proportion of proteomic studies of lung injury focused on pediatric lung injury (pink) versus adult lung injury (grey) over the period 
2005–2015. A total of 186 proteomic studies were performed over this period
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Fig. 2 Age is a major factor in lung disease onset and likely reflects the stage of lung development
Table 1 Overview of proteomic studies of lung injury performed in the pediatric population over the last 10 years
Infection Cystic fibrosis BPD
References Tsai et al. [24] Neumann et al. 
[25]
Frischer et al. [27] MacGregor et al. 
[29]
Sloane et al. [26] Magagnotti et al. 
[15]












Sputum (DTT) BAL (protease 
inhibitor)
Sample number 14 infected, 7 
controls
10 infected, 7 
controls
9 CF, 8 controls 39 CF, 38 controls 7 CF, 5 controls 9 BPD, 3 controls
Method employed 2‑DE, MALDI‑TOF 2‑DE MALDI‑TOF, 
MALDI‑TOF/
TOF‑MS





No No Yes (Calgranulin 
A confirmed by 
western blot)
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western blot)
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were low (n = 9 BPD and n = 3 controls), study partici-
pants were matched on a range of clinical parameters 
ensuring that any changes noted were directly related 
to BPD. A clear separation of the proteome was noted 
amongst the three gestational age groups studied, with 
differential expression noted between the 23–25  week 
group and the 26–29  week group [15]. Identified pro-
teins included calcyphosine (P  =  0.006), calcium and 
integrin binding protein-1 (P = 0.011), chloride channel 
protein 1 (P = 0.001), annexin-3 (P < 0.0001), leukocyte 
elastase inhibitor (SERPINB1; P = 0.002), and pulmonary 
surfactant-associated protein-A2 (STEP-A2; P  =  0.001) 
[15]. To clarify if the differentially expressed proteins 
were linked to gestational age or to the severity of the 
BPD pathology, the authors  employed western blotting 
to quantitate the protein expression of this protein panel 
in BAL from both severe and mildly affected BPD babies 
[15]. When severity of pathology was taken into account 
calcyphosine, calcium and integrin binding protein-1 
and CLIC1, were found to differentiate between mild and 
severe BPD, however Annexin-3 was found to be related 
to development rather than extent of pathology [15].
A major contribution to BPD development is the use 
of mechanical ventilation and consequent development 
of ventilation-induced lung injury (VILI). A 2010 study 
reported that 62  % of extremely preterm infants (gesta-
tion <28  weeks) born in the USA received mechani-
cal ventilation [18], and yet the underlying injury 
mechanisms remain largely unknown. Intriguingly, the 
wide-spread uptake of non-invasive modes of respira-
tory support for the preterm lung has not reduced BPD 
rates in clinical trials [19, 20] or longitudinal datasets 
[21]. This suggests that the mechanistic processes of 
BPD are more complicated than a simple mechani-
cal interaction between a ventilator and the preterm 
lung. The reason why non-invasive respiratory support 
has not reduced BPD has not been elucidated. Map-
ping the VILI-associated proteome, within either serum 
as a reflection of the whole body response or BAL as a 
direct mirror of lung function, would allow mechanisms 
underlying VILI development to be uncovered provid-
ing important and much needed early injury biomarkers 
and the development of improved treatment strategies 
aimed at protecting the lung and minimizing damage. 
Importantly, proteomic analysis allows temporal meas-
urements, accepting that the injury pathways involved 
in BPD are not static events but a continuum of differ-
ent processes occurring over time. Unlike other organs, 
the lung is a mechanical organ that is undergoing con-
tinual movement (breathing) and this can’t be stopped. 
Therefore, any injury pathway once initiated, may not be 
able to be stopped or may even be exacerbated despite 
resolving the initial pathology (preterm birth, aeration, 
surfactant deficiency for example), due to the continuing 
movement of the lung. By employing temporal measure-
ments, proteomics could allow the temporal mapping of 
injury pathways in a variety of pediatric respiratory dis-
ease situations.
Respiratory infections
Respiratory tract infections remain the most common 
cause of pediatric illness, with bronchiolitis and pneumo-
nia having major public health implications worldwide. 
Fortunately, at least in advanced healthcare environ-
ments, most respiratory infections are mild, self-limit-
ing and do not require hospital admission. Despite this 
severe respiratory infections remain a common reason 
for high-dependency support in the infant population, 
especially in ex-premature children. Although rarely 
fatal, severe respiratory infection has significant associ-
ated morbidity. Alterations in the lung proteome due to 
severe respiratory infection have been studied in the set-
ting of pneumococcal pneumonia infection and in the 
setting of respiratory infection whilst immune-compro-
mised. Streptococcus pneumonia is the most common 
cause of bacterial pneumonia in children [22, 23] and 
the serum proteome of children with different severi-
ties of pneumococcal pneumonia (complicated or lobar) 
was compared with a control group [24]. Pneumococcal 
infection was confirmed by either culture of Streptococ-
cus pneumoniae from blood or pleural effusions or a pos-
itive result of pleural pneumococcal antigen. 400 protein 
spots were detected across the two dimensional electro-
phoresis (2-DE) gels, with four protein spots differentially 
expressed across the experimental groups. Secondary 
expression validation via ELISA revealed changes were 
limited to upregulation of haptoglobin (P  =  0.007) and 
immunoglobin kappa chain C region (P  =  0.001) and 
downregulation of transthyretin (P = 0.007) in the com-
plicated pneumonia group compared with the lobar and 
control groups [24]. All of the differentially expressed 
proteins are acute phase proteins and are known to take 
part in inflammation.
Chronic respiratory infections are a major cause of 
morbidity and mortality in children receiving immu-
nosuppressive therapy for malignancies [25]. However 
treatment options are often limited by the inability to 
identify the infectious agent. Therefore Neumann et  al. 
[25], compared the 2D-E profile of BAL samples from 
children with malignancies and fever not responding to 
broad spectrum antibiotics with a control group with the 
aim of classifying the varying types of lung injury and dis-
ease in these differential patients. Pathogens identified in 
BAL fluid included the fungi Paecilomyces and Aspergil-
lus, the virus Cytomegalovirus and the bacterium Staph-
ylococcus epidermidis. The study was limited to 2D-E 
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however proteins were identified which were able to dif-
ferentiate between the controls groups, malignancy with 
no infection and malignancy with infection. In particular, 
α1-antitrypsin was increased in patients with malignan-
cies without pathogens (P  =  0.0027) and transthyretin 
was decreased in the BAL of patients with pathogens 
(P = 0.0313) [25]. Ig binding factor (P = 0.0006) and cys-
tatin S (P = 0.0030) were increased in all malignant sam-
ple sub-groups when compared with controls [25].
Cystic fibrosis
Cystic fibrosis (CF) is the most common fatal single gene 
defect in Caucasian populations [3]. CF is characterized by 
airway inflammation, which occurs within the first months 
of life, chronic bacterial infection, frequent exacerbations 
and ultimately respiratory failure and death [3]. Although 
CF is diagnosed by genetic testing, CF is a multifactorial 
disease whose progression over time is complex and asso-
ciated with various temporal events, such as infectious col-
onization of the lung, nutritional, environmental and even 
social variables. Therapy is also dependent on clinical eval-
uations such as lung function and radiologic changes, both 
of which are likely to lag behind the occurrence of estab-
lished lung pathology [26]. Due to advances in the medical 
care of CF over the last two decades survival into middle 
life is now expected. Formerly purely a pediatric disease, 
CF is now a disease of adulthood too. Central to this has 
been the realization that minimizing cumulative pulmo-
nary deterioration from the recurring cycle of infection 
and inflammation will ultimately help prolong the length 
and improve the quality of life for an individual with CF 
[26]. Hence proteomic studies of CF have focused on iden-
tifying protein signatures within BAL, sputum or serum 
which are specific to CF pathopathology with the aim of 
developing rapid and repeatable diagnostic and prognostic 
tools to assist with the clinical assessment of lung function 
and disease progression.
Three studies have examined alterations in the CF pro-
teome in bronchial tissue [27], BAL or sputum. In a study 
of bronchial tissue obtained from patients with CF or 
controls, three proteins were increased in CF tissue; glu-
cose regulated protein (GRP75; P = 0.002) a member of 
the heat shock protein family, respiratory chain enzyme 
ubiquinol-cytochrome c reductase complex core protein 
I (P = 0.005) which has links to hypoxia [28], and nido-
gen (P = 0.002) whose functional role is unknown. Pro-
teomic examination of BAL fluid obtained from children 
with CF and controls yielded 167 proteins which were 
increased and 35 which were decreased in CF patients 
relative to controls (P  <  0.001), however only three of 
the proteins were identified; s100 A8 (calgranulin A; 
P < 0.05), s100 A9 (calgranulin B), s100 A12 (calgranulin 
C) [29]. However the results of both of these studies 
may be compromised by the choice of control group, as 
in both studies the control group also exhibited active 
microbial infection.
Sloane et al. [26] further extended current CF proteome 
studies by comparing the protein profile of sputum from 
adults and children with CF. Whilst only three proteins 
were identified, an advantage to this study was the iden-
tification of a pediatric specific versus adult specific CF 
proteome. Therefore highlighting the need to study child-
hood samples rather than infer results from adult studies 
of lung disease in which the parameters are different. In 
particular Sloane et al., identified numerous IgG-γ1 heavy 
chain fragments within adult sputum whilst the sputum 
from children with CF largely only contained full length 
IgG heavy and light chains [26].
Asthma
Wheezing in preschool children is very common with 
one in three preschool children experiencing an episode 
of wheezing before their third birthday [30]. In the major-
ity of children wheezing will cease by the age of 6 years, 
however one-third will develop a persistent wheeze and 
asthma [30], and there are no known predictors. Differ-
entiating asthma, or a prodromal state that may progress 
to asthma, in the preschool child is difficult. Physi-
cal examination is rarely diagnostic alone, and the gold 
standard diagnostic test is demonstration of altered pul-
monary function and response to bronchodilators during 
pulmonary function testing. Although, pulmonary func-
tion testing is a valid and longstanding diagnostic tool 
in adults and older children they are labor and expertise 
intensive. In the non-compliant preschool child generat-
ing maximal expiratory flow-volume maneuvers is chal-
lenging and reliable diagnosis difficult. Hence, practically, 
clinicians often make the early diagnosis of asthma based 
on nonspecific aspects of the clinical history and exami-
nation of the child coupled with clinical acumen. Fur-
thermore, whilst the mainstay of asthma therapy remains 
the use of bronchodilators and corticosteroids, not all 
asthma sufferers respond similarly to treatment with cor-
ticosteroids [31], and response predictors are not avail-
able. Within this context, reliable biomarkers to identify 
both those young wheezing children likely to develop 
asthma later, and target specific therapies pathways has 
the potential to reduce medical costs, and improve the 
quality of life of young wheezing children [31]. Proteomic 
analysis of serum or direct respiratory tract samples 
from preschool children with or without a wheeze may 
uncover new predictors of disease outcome, allow strati-
fication of wheeze-type and allow prediction of treatment 
response.
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Conclusion
Proteomics, the large-scale study of the structure and 
function of proteins of a cell or organism, is a rapidly 
developing area of biomedical research which is perfectly 
suited to the study of the developmental and transla-
tional nature of pediatric lung injury and yet only 4 % of 
proteomic studies aimed at lung injury and disease have 
focused on pediatric lung disease.
A number of key differences between the pediatric and 
adult study populations inhibit inference of results from 
adult studies onto a pediatric population and necessi-
tate studies of the pediatric proteome. These differences 
include fundamental differences in the response to dis-
ease by an immature respiratory system versus the devel-
oped lung, the concept of the pediatric lung as a dynamic 
changing developmental organ and disparity amongst 
pediatric lung disease in terms of age at onset and under-
lying pathological mechanism (genetic, immunological, 
intervention-based, developmental arrest, inhaled toxin). 
Such differences will require proteomic studies which 
are well designed, with large disease specific patient sets 
to ensure adequate power as well as matched controls. 
Regardless of the causative agent pulmonary biomarkers 
are needed to predict the clinical course of pediatric lung 
disease, status, progression and response to treatment. 
Identification of early biomarkers is particularly pertinent 
in order to alter the natural history of the disease and 
prevent ongoing lung injury and impact into adulthood.
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